A detailed history of Argyle Capital Management Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Argyle Capital Management Inc. holds 3,500 shares of ABBV stock, worth $630,000. This represents 0.28% of its overall portfolio holdings.

Number of Shares
3,500
Previous 3,500 -0.0%
Holding current value
$630,000
Previous $600,000 15.17%
% of portfolio
0.28%
Previous 0.25%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 29, 2024

SELL
$154.79 - $180.76 $255,403 - $298,254
-1,650 Reduced 32.04%
3,500 $600,000
Q1 2024

Apr 29, 2024

SELL
$159.82 - $182.1 $15,982 - $18,210
-100 Reduced 1.9%
5,150 $937,000
Q4 2023

Feb 05, 2024

SELL
$137.6 - $154.97 $474,720 - $534,646
-3,450 Reduced 39.66%
5,250 $813,000
Q2 2023

Jul 27, 2023

SELL
$132.51 - $164.9 $265,020 - $329,800
-2,000 Reduced 18.69%
8,700 $1.17 Million
Q4 2022

Feb 06, 2023

SELL
$138.31 - $165.87 $96,817 - $116,109
-700 Reduced 6.14%
10,700 $1.73 Million
Q3 2022

Oct 21, 2022

SELL
$134.21 - $153.93 $26,842 - $30,786
-200 Reduced 1.72%
11,400 $1.53 Million
Q3 2021

Oct 25, 2021

SELL
$106.4 - $120.78 $26,600 - $30,195
-250 Reduced 2.11%
11,600 $1.25 Million
Q1 2021

Apr 27, 2021

SELL
$102.3 - $112.62 $20,460 - $22,524
-200 Reduced 1.66%
11,850 $1.28 Million
Q4 2020

Jan 28, 2021

SELL
$80.49 - $108.67 $20,122 - $27,167
-250 Reduced 2.03%
12,050 $1.29 Million
Q2 2020

Jul 22, 2020

SELL
$73.37 - $98.18 $7,337 - $9,818
-100 Reduced 0.81%
12,300 $1.21 Million
Q3 2018

Oct 26, 2018

SELL
$88.91 - $98.84 $22,227 - $24,710
-250 Reduced 1.98%
12,400 $1.17 Million
Q3 2017

Oct 26, 2017

BUY
$69.85 - $89.22 $883,602 - $1.13 Million
12,650
12,650 $1.12 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Argyle Capital Management Inc. Portfolio

Follow Argyle Capital Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Argyle Capital Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Argyle Capital Management Inc. with notifications on news.